Really insightful write-up! Retatrutide definitely looks like a breakthrough in metabolic research, especially with its triple-action approach targeting GLP-1, GIP, and glucagon receptors. I appreciate how clearly you explained the difference compared to compounds like semaglutide and tirzepatide. It’s exciting to see how this could shape the future of obesity and diabetes studies. Looking forward to more updates as clinical research progresses. Status